Melanoma vs Non-Melanoma: A Complete Guide to Skin Cancer Types

A moment of neglect under the sun may plant the seeds of risk years later; an inconspicuous mole may quietly begin to change—this is the hidden danger of skin cancer. As one of the fastest-growing cancers worldwide, skin cancer has long relied on surgery and radiotherapy, with limited options and poor prognosis for some advanced patients.

Skin cancer is the uncontrolled growth of abnormal cells in the outermost layer of the skin. DNA damage caused by ultraviolet (UV) radiation from sunlight or tanning beds is the primary carcinogenic factor. Based on the nature of cancer cells, skin cancer can be broadly divided into melanoma and non-melanoma types, which differ significantly in incidence, malignancy, treatment complexity, and prognosis. Global pharmaceutical distributor DengYueMed provides a comprehensive analysis of these two types to help readers better understand and prevent this increasingly prevalent disease.

1. Melanoma vs Non-Melanoma: Key Differences

Melanoma originates from melanocytes (cells responsible for skin pigmentation), while non-melanoma skin cancers mainly arise from keratinocytes. This fundamental difference leads to distinct biological behaviors.

Melanoma is highly malignant and aggressive. Even in early stages, it can metastasize to other organs. Studies show that the 5-year survival rate for Stage I melanoma exceeds 94%, but once metastasis occurs, the 5-year survival rate for Stage IV drops to below 5%. Melanoma often develops from existing moles or newly formed pigmented lesions when melanocytes undergo DNA mutations due to UV damage, leading to uncontrolled growth.

Non-melanoma skin cancers account for approximately 85%–90% of all skin cancer cases. Although far more common than melanoma, they are generally less aggressive, grow slowly, and are easier to treat. Most cases can be cured through surgical excision. However, if left untreated, some non-melanoma skin cancers may enlarge or spread internally.

2. Non-Melanoma Skin Cancer

Non-melanoma skin cancers mainly include basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), as well as rarer types such as Merkel cell carcinoma and Kaposi’s sarcoma.

● Basal Cell Carcinoma (BCC)

The most common type, accounting for 45%–60%. It often appears on the face as pearly nodules with visible blood vessels or ulceration. It has low malignancy and rarely metastasizes. Surgical excision or radiotherapy is usually curative.

● Squamous Cell Carcinoma (SCC)

The second most common type, accounting for 30%–35%. It frequently occurs on sun-exposed areas such as the face and back of the hands. Early lesions appear as red, firm nodules that may develop into cauliflower-like ulcers. It grows faster than BCC, and a small percentage may metastasize to lymph nodes. Surgical excision is the main treatment, especially for lesions on the ears or lips, which require aggressive management.

3. Melanoma

Melanoma is the most aggressive form of skin cancer. Although its incidence is lower than BCC and SCC, it has a high metastatic rate, treatment difficulty, and mortality, earning it the nickname “the king of cancers.”

● Clinical Subtypes

Unlike Western populations, where cutaneous melanoma is more common, melanoma in China is often acral or mucosal, both of which are more aggressive. Acral melanoma accounts for about 50% and typically occurs on the palms, soles, or under the nails, with a higher risk of subcutaneous or skin metastasis. Mucosal melanoma accounts for about 20% and arises in areas such as the digestive tract, nasal cavity, paranasal sinuses, and genitourinary tract, with poorer prognosis.

● Clinical Manifestations

Early signs include new dark lesions on normal skin or noticeable changes in existing moles, such as enlargement or increased pigmentation. Over time, lesions may become raised, form nodules, ulcerate, and bleed. Patients may notice new moles with irregular growth, bleeding, itching, color changes, or ulceration.

● Disease Characteristics

Approximately 25% of melanoma patients in China harbor BRAF gene mutations. These patients often experience faster tumor progression, with a higher likelihood of multiple subcutaneous and brain metastases. BRAF mutations are more common in younger patients.

● Treatment Advances

Significant progress has been made in melanoma treatment in recent years. Early-stage melanoma is primarily treated with surgical excision. For advanced disease, immunotherapy and targeted therapy have become essential. Targeted drugs such as vemurafenib show response rates exceeding 50% and disease control rates above 95% in patients with BRAF mutations.

4. Overview of Treatment Strategies

● Treatment of Non-Melanoma Skin Cancer

Treatment options include surgery, cryotherapy, radiotherapy, chemotherapy, and topical medications, with surgery being the most common approach. BCC is highly sensitive to radiotherapy and has high cure rates. SCC is primarily treated with surgical excision, with adjuvant radiotherapy or chemotherapy as needed. Early-stage carcinoma in situ can also be treated with cryotherapy, topical chemotherapy agents, or laser therapy.

● Treatment of Melanoma

Melanoma treatment is more complex. Early-stage disease is mainly managed with surgical excision. With the advancement of immunotherapy and targeted therapy, treatment options for advanced patients have significantly expanded. Anti–PD-1 antibodies are now first-line systemic therapy for metastatic or locally advanced disease. Targeted therapies such as vemurafenib provide new hope for patients with BRAF mutations. Neoadjuvant immunotherapy is also emerging as an important area of exploration.

Conclusion

In the era of precision medicine, access to cutting-edge treatment information and high-quality medical resources is increasingly important. Through platforms like DengYueMed, which specialize in integrating global innovative drugs and medical services, patients can more efficiently access the latest international treatment advancements and connect with professional healthcare institutions. This enables more personalized treatment options based on standardized care.

Looking ahead, with the continued integration of precision medicine and regenerative technologies, skin cancer is expected to enter a new era—one that is more controllable, treatable, and even repairable.